WikiJournalClub:Usable articles: Difference between revisions

Jump to navigation Jump to search

WikiJournalClub:Usable articles (view source)

Revision as of 00:06, 2 April 2016

1,197 bytes added ,  2 April 2016
no edit summary
No edit summary
No edit summary
Line 297: Line 297:
* [[Annane Trial]] (2002): Corticosteroids in septic shock
* [[Annane Trial]] (2002): Corticosteroids in septic shock
* [[ARISE]] (2014): EGDT vs. usual care in sepsis
* [[ARISE]] (2014): EGDT vs. usual care in sepsis
* [[CORTICUS]] (2008): Hydrocortisone in septic shock
* [[ProCESS]] (2014): EGDT in septic shock
* [[ProCESS]] (2014): EGDT in septic shock
* [[PROWESS]] (2001): Activated protein C in severe sepsis
* [[PROWESS]] (2001): Activated protein C in severe sepsis
Line 308: Line 309:
'''Shock'''
'''Shock'''
* [[Annane Trial]] (2002): Corticosteroids in septic shock
* [[Annane Trial]] (2002): Corticosteroids in septic shock
* [[CORTICUS]] (2008): Hydrocortisone in septic shock
* [[CRISTAL]] (2013): Colloids vs. crystalloids in shock
* [[CRISTAL]] (2013): Colloids vs. crystalloids in shock
* [[FEAST]] (2011): Fluid resuscitation in Sub-Saharan Africa
* [[FEAST]] (2011): Fluid resuscitation in Sub-Saharan Africa
Line 377: Line 379:


'''Diabetes Mellitus'''
'''Diabetes Mellitus'''
* [[ACCORD]] (2008): Intensive glycemic therapy in T2DM
* [[ACCORD BP]] (2010): Intensive BP control in T2DM
* [[ACCORD BP]] (2010): Intensive BP control in T2DM
* [[ADVANCE]] (2008): Intensive glycemic therapy in T2DM
* [[ADVANCE]] (2008): Intensive glycemic therapy in T2DM
Line 384: Line 387:
* [[EDIC]] (2005): Intensive glycemic therapy in T1DM
* [[EDIC]] (2005): Intensive glycemic therapy in T1DM
* [[EMPA-REG OUTCOME]] (2015): Empagliflozin for CV outcomes in T2DM
* [[EMPA-REG OUTCOME]] (2015): Empagliflozin for CV outcomes in T2DM
* [[IDNT]] (2001): ARBs in diabetic nephropathy
* [[Look AHEAD]] (2013): Weight loss and exercise in T2DM
* [[Look AHEAD]] (2013): Weight loss and exercise in T2DM
* [[ONTARGET]] (2008): Ramipril vs. telmisartan vs. both in CVD, stroke, PAD, or DM
* [[ONTARGET]] (2008): Ramipril vs. telmisartan vs. both in CVD, stroke, PAD, or DM
Line 396: Line 400:
'''Diabetic Nephropathy'''
'''Diabetic Nephropathy'''
* [[CSG Captopril Trial]] (1993): Captopril in T1DM nephropathy
* [[CSG Captopril Trial]] (1993): Captopril in T1DM nephropathy
* [[IDNT]] (2001): ARBs in diabetic nephropathy
* [[VA-NEPHRON D]] (2013): ACE+ARB in DM nephropathy
* [[VA-NEPHRON D]] (2013): ACE+ARB in DM nephropathy


Line 403: Line 408:
'''Obesity'''
'''Obesity'''
* [[STAMPEDE]] (2012): Gastric bypass vs. medical therapy for T2DM
* [[STAMPEDE]] (2012): Gastric bypass vs. medical therapy for T2DM
'''Sepsis'''
* [[CORTICUS]] (2008): Hydrocortisone in septic shock
'''Shock'''
* [[CORTICUS]] (2008): Hydrocortisone in septic shock


'''Stress Hyperglycemia'''
'''Stress Hyperglycemia'''
Line 416: Line 427:
* [[Prednisolone in Severe Alcoholic Hepatitis]] (1992): Prednisolone vs. placebo in alcoholic hepatitis
* [[Prednisolone in Severe Alcoholic Hepatitis]] (1992): Prednisolone vs. placebo in alcoholic hepatitis
* [[STOPAH]] (2015): Prednisolone vs. pentoxifylline in alcoholic hepatitis
* [[STOPAH]] (2015): Prednisolone vs. pentoxifylline in alcoholic hepatitis
'''Cirrhosis'''
* [[Antibiotics in Cirrhosis with Hemorrhage]] (2006): Ceftriaxone vs. norfloxacin in cirrhotics with GI bleed


'''Clostridium difficile'''
'''Clostridium difficile'''
Line 426: Line 440:


'''Gastrointestinal Hemorrhage'''
'''Gastrointestinal Hemorrhage'''
* [[Antibiotics in Cirrhosis with Hemorrhage]] (2006): Ceftriaxone vs. norfloxacin in cirrhotics with GI bleed
* [[GI bleeding in ICU patients]] (1994): Risk factors for GI bleeds in ICU patients
* [[GI bleeding in ICU patients]] (1994): Risk factors for GI bleeds in ICU patients
* [[Omeprazole in Peptic Ulcer Bleeding]] (2000): IV PPI for GI bleeds
'''Hepatic Encephalopathy'''
* [[Rifaximin and Lactulose for HE]] (2013): Rifaximin/lactulose vs. lactulose for acute HE


'''Hepatitis C'''
'''Hepatitis C'''
Line 534: Line 553:


==Infectious Disease==
==Infectious Disease==
'''Cirrhosis'''
* [[Antibiotics in Cirrhosis with Hemorrhage]] (2006): Ceftriaxone vs. norfloxacin in cirrhotics with GI bleed
'''Clostridium difficile'''
'''Clostridium difficile'''
* [[Fidaxomicin in C. difficile Diarrhea]] (2011): Fidaxomicin in C. difficile
* [[Fidaxomicin in C. difficile Diarrhea]] (2011): Fidaxomicin in C. difficile
Line 542: Line 564:
* [[3SITES]] (2015): Central line complications by insertion site
* [[3SITES]] (2015): Central line complications by insertion site
* [[PRORATA]] (2010): Procalcitonin-guided antibiotics
* [[PRORATA]] (2010): Procalcitonin-guided antibiotics
'''Gastrointestinal Hemorrhage'''
* [[Antibiotics in Cirrhosis with Hemorrhage]] (2006): Ceftriaxone vs. norfloxacin in cirrhotics with GI bleed


'''HIV'''
'''HIV'''
Line 599: Line 624:
'''Diabetes Mellitus'''
'''Diabetes Mellitus'''
* [[CSG Captopril Trial]] (1993): Captopril in T1DM nephropathy
* [[CSG Captopril Trial]] (1993): Captopril in T1DM nephropathy
* [[IDNT]] (2001): ARBs in diabetic nephropathy
* [[ONTARGET]] (2008): Ramipril vs. telmisartan vs. both in CVD, stroke, PAD, or DM
* [[ONTARGET]] (2008): Ramipril vs. telmisartan vs. both in CVD, stroke, PAD, or DM
* [[RENAAL]] (2001): ARBs in diabetic nephropathy
* [[RENAAL]] (2001): ARBs in diabetic nephropathy
Line 606: Line 632:
'''Diabetic Nephropathy'''
'''Diabetic Nephropathy'''
* [[CSG Captopril Trial]] (1993): Captopril in T1DM nephropathy
* [[CSG Captopril Trial]] (1993): Captopril in T1DM nephropathy
* [[IDNT]] (2001): ARBs in diabetic nephropathy
* [[VA-NEPHRON D]] (2013): ACE+ARB in DM nephropathy
* [[VA-NEPHRON D]] (2013): ACE+ARB in DM nephropathy


WJCBot
Bots, editor, reviewer, Administrators
13,941

edits

Retrieved from "http://www.wikijournalclub.org/wiki/Special:MobileDiff/21784"

Navigation menu